A2B adenosine receptor blockade inhibits growth of prostate cancer cells

@article{Wei2012A2BAR,
  title={A2B adenosine receptor blockade inhibits growth of prostate cancer cells},
  author={Qiang Wei and Stefano Costanzi and Ramachandran Balasubramanian and Zhang-Guo Gao and Kenneth A. Jacobson},
  journal={Purinergic Signalling},
  year={2012},
  volume={9},
  pages={271-280}
}
The role of the A2B adenosine receptor (AR) in prostate cell death and growth was studied. The A2B AR gene expression quantified by real-time quantitative RT-PCR and Western blot analysis was the highest among four AR subtypes (A1, A2A, A2B, and A3) in all three commonly used prostate cancer cell lines, PC-3, DU145, and LNCaP. We explored the function of the A2B AR using PC-3 cells as a model. The A2B AR was visualized in PC-3 cells by laser confocal microscopy. The nonselective A2B AR agonist… 
Blockade of Adenosine A2b Receptor Reduces Tumor Growth and Migration in Renal Cell Carcinoma
TLDR
The findings suggest the A2BR potentially plays an important role in RCC progression and A2bR blockade may be a promising candidate for therapeutic intervention for renal cell carcinoma.
Activation of A2b adenosine receptor regulates ovarian cancer cell growth: involvement of Bax/Bcl-2 and caspase-3.
TLDR
It is demonstrated that NECA induces apoptosis via the mitochondrial signaling pathway, suggesting that A2bAR agonists may be a potential agent for induction of apoptosis in ovarian cancer cells.
Adenosine A2b receptor promotes progression of human oral cancer
TLDR
It is suggested that ADORA2B controls cellular proliferation via HIF-1α activation, indicating that ADORN2B may be a key regulator of tumoral progression in OSCCs.
A2B adenosine receptor agonist induces cell cycle arrest and apoptosis in breast cancer stem cells via ERK1/2 phosphorylation
TLDR
It is concluded that A2BAR induces breast CSC cell cycle arrest and apoptosis through downregulation of the ERK1/2 cascade and may be considered as a novel target for the treatment of breast cancer.
Ligand-Independent Adenosine A2B Receptor Constitutive Activity as a Promoter of Prostate Cancer Cell Proliferation
TLDR
This study is the first to reveal that wild-type human A2BARs have high constitutive activity in both model and native cells, and demonstrates that this ligand-independent A 2BAR constitutiveActivity is sufficient to promote prostate cancer cell proliferation in vitro.
Activation of the A2B adenosine receptor in B16 melanomas induces CXCL12 expression in FAP-positive tumor stromal cells, enhancing tumor progression
TLDR
It is reported that pharmacologic inhibition of A2BR with PSB1115, which inhibits tumor growth, decreased the number of fibroblast activation protein (FAP)-expressing cells in tumors in a mouse model of melanoma.
Adenosine A2A receptor ligand recognition and signaling is blocked by A2B receptors
TLDR
A2A-A2BAR heteromers represent novel pharmacological targets and have major implications for the use of A2AAR ligands as drugs as they will fail to modulate the receptor in an A2 a-a2B heteromer context.
A2B Adenosine Receptor and Cancer
TLDR
The signaling, agonists, and antagonists of the A2BAR are described, which are one of the several GPCRs that are expressed in a significantly higher level in certain cancer tissues, in comparison to adjacent normal tissues.
The adenosine A2b receptor promotes tumor progression of bladder urothelial carcinoma by enhancing MAPK signaling pathway
TLDR
The present study indicates that A2bR may play a potential oncogenic role in BUC progression and act as a potential biomarker to identify BUC patients with poor clinical outcomes.
...
...

References

SHOWING 1-10 OF 24 REFERENCES
Targeting the A3 adenosine receptor for cancer therapy: inhibition of prostate carcinoma cell growth by A3AR agonist.
TLDR
It is demonstrated that A3AR activation deregulates the Wnt and the NF-kappa B signaling pathways resulting in the inhibition of prostate carcinoma cell growth.
Adenosine A2B Receptor Blockade Slows Growth of Bladder and Breast Tumors
The accumulation of high levels of adenosine in tumors activates A2A and A2B receptors on immune cells and inhibits their ability to suppress tumor growth. Deletion of adenosine A2A receptors
Effects of extracellular nucleotides and nucleosides on prostate carcinoma cells
TLDR
It is suggested that P2X receptors might be involved in the inhibition by nucleotides of prostate carcinoma cell growth.
Hypoxia-inducible adenosine A2B receptor modulates proliferation of colon carcinoma cells.
Adenosine A2A and A2B receptor expression in neuroendocrine tumours: potential targets for therapy
TLDR
The data suggest that neuroendocrine tumours predominantly express A2A and A2B adenosine receptors; their activation leads to increased proliferation and secretion of chromogranin A.
Adenosine Receptor Expression in Two Different Human Cancer Cell Lines at Molecular Level
TLDR
The hypothesis that diverse human cancer cell lines, according to their adenosine receptor subclass status, would show differential growth modulation is tested, and the differentially expressed genes identified in this study might provide new insights into the possible roles ofAdenosine receptors on cell growth and development.
Vascular CD39/ENTPD1 directly promotes tumor cell growth by scavenging extracellular adenosine triphosphate.
TLDR
It is demonstrated that exogenous soluble NTPDase, or CD39 expression by cocultured liver sinusoidal endothelial cells, stimulates tumor cell proliferation and limits cell death triggered by extracellular ATP, and pharmacological or targeted inhibition of CD39 enzymatic activity may find utility as an adjunct therapy in cancer management.
Host A(2B) adenosine receptors promote carcinoma growth.
TLDR
The data suggest that tumor cells promote their growth by exploiting A(2B) adenosine receptor-dependent regulation of VEGF in host immune cells.
Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis
TLDR
This study identified tumor-derived CD73 as a mechanism of tumor immune escape and tumor metastasis, and established the proof of concept that targeted therapy against CD73 can trigger adaptive anti-tumor immunity and inhibit metastasis of breast cancer.
...
...